A proven model for biopharmaceutical growth.
Innoviva is a diversified biopharmaceutical company built for creating value across healthcare.
$430M
LTM royalty and net product revenue1
5
FDA-approved products
$600M
In cash & cash equivalents1
$700M
In strategic healthcare investments1
1. Approximate values as of 2Q26
A DIFFERENT MODEL
Three business pillars.
One unified growth engine.
Durable royalty streams provide downside protection, while growing commercial products and high-potential healthcare investments enable upside exposure.
Innoviva Specialty Therapeutics
A commercial-stage therapeutics business bringing differentiated medicines to patients with critical unmet needs.
Royalty
Assets
Resilient royalty income streams from established respiratory products.
Strategic Healthcare Assets
Selective investments in differentiated healthcare companies where our capital and expertise can unlock meaningful long-term value.
